These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21098319)

  • 1. Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma.
    Blombery P; Prince HM; Levinson M; Pianko S; Maxwell E; Bhathal P
    J Clin Oncol; 2011 Feb; 29(5):e110-2. PubMed ID: 21098319
    [No Abstract]   [Full Text] [Related]  

  • 2. Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders?
    Hincks I; Woodcock BE; Thachil J
    Br J Haematol; 2011 May; 153(3):411-3. PubMed ID: 21275972
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe anemia during rituximab maintenance therapy for follicular lymphoma.
    Liapis K; Harhalakis N; Stefanou G; Apostolidis J
    J Clin Oncol; 2012 Mar; 30(8):e95-6. PubMed ID: 22231048
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid-onset, prolonged bone marrow failure following rituximab therapy of follicular lymphoma.
    Debatin L; Schmitt-Graeff A; Veelken H
    Onkologie; 2011; 34(6):322-4. PubMed ID: 21625186
    [No Abstract]   [Full Text] [Related]  

  • 5. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG.
    Saikia TK; Menon H; Advani SH
    Ann Oncol; 2001 Oct; 12(10):1493-4. PubMed ID: 11762825
    [No Abstract]   [Full Text] [Related]  

  • 6. Focal rituximab-induced edematous reaction at primary cutaneous follicle center lymphoma lesions: case report and literature review.
    Brunet-Possenti F; Franck N; Tamburini J; Jacobelli S; Avril MF; Dupin N
    Dermatology; 2011; 223(3):200-2. PubMed ID: 21986026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab maintenance therapy for follicular lymphoma.
    Zhou H; Zhang B; Zhang J; Ni W; Hu Z
    Lancet; 2011 Apr; 377(9772):1150-1; author reply 1151-2. PubMed ID: 21459204
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab-related cryptogenic organizing pneumonia and late onset neutropenia in a patient with non-Hodgkin lymphoma: report of two rare complications and review of the literature.
    Urun Y; Dincol D; Kumbasar OO
    J BUON; 2012; 17(3):602-3. PubMed ID: 23033310
    [No Abstract]   [Full Text] [Related]  

  • 9. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab-induced subacute interstitial pneumonitis: a case report and review of literature.
    Subramanian M; Manjunath R; Kilara N; Mohan Rao KN
    J Cancer Res Ther; 2010; 6(3):344-6. PubMed ID: 21119272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignancies after rituximab treatment: just coincidence or more?
    Aksoy S; Arslan C; Harputluoglu H; Dizdar O; Altundag K
    J BUON; 2011; 16(1):112-5. PubMed ID: 21674860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rituximab-induced interstitial lung disease].
    Fernández Casares M; Espósito G; González A; Segovia J; Galperín Mde L; Del Valle E
    Medicina (B Aires); 2013; 73(4):343-5. PubMed ID: 23924535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
    Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
    J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab: therapeutic benefit! Vitamin R?
    Mo C; Vire B; Wiestner A
    Semin Hematol; 2010 Apr; 47(2):105-6. PubMed ID: 20350656
    [No Abstract]   [Full Text] [Related]  

  • 15. Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.
    Zhang B; Wang J; Xu W; Wang L; Ni W
    Onkologie; 2010; 33(10):537-9. PubMed ID: 20926902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rituximab (antiCD20 monoclonal antibody) and molecular-biological negativity in the treatment of patients with follicular lymphoma--a way to a cure?--Editorial].
    Trnený M
    Vnitr Lek; 2007 Oct; 53(10):1029-30. PubMed ID: 18072423
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab-related urticarial reaction overlying primary cutaneous follicle centre lymphoma: histological appearance and pathophysiological hypotheses.
    Ingen-Housz-Oro S; Ortonne N; Chosidow O
    J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):976-8. PubMed ID: 24206369
    [No Abstract]   [Full Text] [Related]  

  • 18. Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation.
    Puig N; Caballero MD; Alcoceba M; Sebastián E; Balanzategui A; Sarasquete ME; García-Sanz R; González-Díaz M
    Ann Hematol; 2011 Feb; 90(2):227-9. PubMed ID: 20506021
    [No Abstract]   [Full Text] [Related]  

  • 19. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms.
    Tesfa D; Palmblad J
    Expert Rev Hematol; 2011 Dec; 4(6):619-25. PubMed ID: 22077526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab-containing chemotherapy.
    Kusumoto S; Tanaka Y; Mizokami M; Ueda R
    Hepatology; 2014 Aug; 60(2):765-6. PubMed ID: 24347499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.